A blood test developed by Natera could detect early stage breast cancer relapse nearly two years quicker than current imaging technologies.
Called Signatera, the test conducts molecular residual disease (MRD) analysis to identify trace amounts of mutated DNA produced by dying tumours.
A research study by the University of Leicester and Imperial College London in the UK has demonstrated that Signatera identified 89% of all relapses around 8.9 months earlier than imaging techniques.